PD-1 & CTLA4

$0.00

Description

Generation Strategy

Strategy for Generating Humanized PD-1 (ASHU-00015) Mouse Model

landingpage-ashu-00079-pd-1&ctla4-hu-icpmouse-1

Strategy for Generating Humanized CTLA4 (ASHU-00014) Mouse Model

landingpage-ashu-00079-pd-1&ctla4-hu-icpmouse-2

The Expression of hPD-1 in Stimulated T Cells from Double Humanized PD-1 & CTLA4 Mice 

landingpage-ashu-00079-pd-1&ctla4-hu-icpmouse-3

landingpage-ashu-00079-pd-1&ctla4-hu-icpmouse-4

Figure 1. The expression of human CTLA-4 in double humanized PD-1 & CTLA-4 mice was confirmed by FACS.

landingpage-ashu-00079-pd-1&ctla4-hu-icpmouse-5

Figure 2. In vivo validation of double humanized PD-1 & CTLA-4 mice. The Double humanized mice were inoculated with MC38 cells, and randomly assigned to different groups (n=8) when the tumor grew to a volume of 100 mm3. A combinatorial treatment of anti-CTLA-4 and anti-PD-1 demonstrated a noticeable improvement in efficacy as compared to the same dose of single agent (top figure) without affecting the animal body weight (bottom).

landingpage-ashu-00079-pd-1&ctla4-hu-icpmouse-6

Figure 3. As shown in the previous figure, animals of group 1-4 received different doses of either single agent or combinatorial treatment. This graph showed the progression of the tumor implanted in the cured, G4 mice, implicating a systematic anti-tumor effect induced by the combinatorial antibody treatment.